A refinement to this approach is to use compounds that can exploit the presence of DNA damage in cancer cells. Given that replication stress (RS) is a major source of genomic instability in cancer, targeting the RS-response kinase ataxia telangiectasia and Rad3-related protein (ATR) has ...
Among them, the targeting of ATR has significant therapeutic potential in treating cancer with defective DDR signaling.We reviewed the essential role of ATR in the DDR pathway, especially with cancer development, and comprehensively focused on the preclinical investigations to reveal the therapeutic ...
Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs Trying to kill cancer cells by generating DNA damage is by no means a new idea. Radiotherapy and genotoxic drugs are routinely used in cancer therapy. More... LI Toledo,M Murga,O Fernandez-...
ATR Chk1 Cancer therapy 1. The RSR: time to fly solo from the DDR DNA double-strand breaks (DSB) are amongst the most deleterious lesions that cells can suffer. Their presence can trigger genome rearrangements and the loss of genetic information at the break site. As a consequence, the pr...
摘要: ATR inhibitors are a new class of anti-cancer compounds reaching early phase clinical trials. They are predicted to have anti-cancer activity as monotherapy, and in combination with DNA damaging...DOI: 10.1007/978-3-319-75836-7_5 ...
Targeting metabolic reprogramming in KRAS-driven cancers Introduction Oncogenic Kirsten Rat sarcoma viral oncogene homolog (KRAS) mutations are one of the most common and challenging drivers of human cancer, particularly in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and...
The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific
g A model for SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting Topoisomerase II. See text for details. Full size image To rule out the possible involvement of other β-TrCP substrates in VM-26 sensitization, we stably ...
Chromosomal instability (CIN) is a hallmark of cancer and a driver of metastatic dissemination, therapeutic resistance, and immune evasion. CIN is present in 60–80% of human cancers and poses a formidable therapeutic challenge as evidenced by the lack o
metastasis. Many mTOR inhibitors have been developed to treat cancer. While some of the mTOR inhibitors have been approved to treat human cancer, more mTOR inhibitors are being evaluated in clinical trials. Here, we update recent advances in exploring mTOR signaling and the development of mTOR ...